My work is in molecular biology and biotechnology, with a focus on designing and manipulating biological systems for targeted therapies and drug delivery. Over time, I have moved toward questions that sit at the intersection of recombinant protein engineering, cancer biology, and nanotechnology. I am especially interested in platforms that define components, particularly a specific ligand, a specific carrier, and a well‑characterized target in the tumor or its microenvironment. My current interest is drug delivery using bacterial Outer Membrane Vesicles (OMVs). I view OMVs as a flexible biological platform. Because they are naturally produced vesicles, they can be engineered at the level of the bacterial strain so that specific proteins or ligands appear on their surface. I am interested in surface-engineered OMVs that carry tumor-targeting moieties, such as affibodies, fusogenic peptides, or receptor-binding ligands (e.g., octreotide-based ligands for SSTR2). The aim is to help these vesicles find and bind specific tumor or stromal cells, deliver a defined payload to them, and use this approach to actively modify the tumor microenvironment, especially in immunocold tumors, so that it becomes more permissive to effective anti-tumor immune responses and other therapies.